Top
Press Releases / Notices2022

Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

by Year

2025
2024
2023
2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009

by Category

Corporate
Management & Finance
Pharmaceuticals
R & D
Sustainability
Food Business
Other
Notices

NEWS 2022

December 23, 2022 Pharmaceuticals PDF326 KB

Humanized Anti-CD20 Monoclonal Antibody Gazyva Approved for Additional Indication of Chronic Lymphocytic Leukemia
December 20, 2022 R & D PDF230 KB

NS-018, Treatment for Myelofibrosis under development in overseas received Orphan Drug Designation from the U.S. FDA
November 16, 2022 Pharmaceuticals PDF275 KB

Launch of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Dravet syndrome in Japan
November 10, 2022 Management & Finance PDF280 KB

Revision of Performance Projection, Dividend of Surplus (Interim Dividend) and Revision of Year-end Dividend Forecast
November 10, 2022 Management & Finance

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2022
October 26, 2022 Management & Finance PDF118 KB

Revision of Performance Projection
October 24, 2022 R & D PDF269 KB

VILTEPSO® (viltolarsen) injection: Four-Year Clinical Trial Data Presented at the World Muscle Society 2022 Conference
October 03, 2022 R & D PDF261 KB

VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference
September 26, 2022 Pharmaceuticals PDF286 KB

Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome
August 09, 2022 Management & Finance

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2022
July 15, 2022 Corporate PDF310 KB

Nippon Shinyaku Selected as a Constituent of the FTSE Blossom Japan Sector Relative Index, a New ESG Index
June 02, 2022 Notices

Notice Of The 159th Annual General Meeting Of Shareholders
May 31, 2022 R & D PDF240 KB

VILTEPSO® (viltolarsen): Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases
May 30, 2022 R & D PDF254 KB

Orphan Drug Designation granted to NS-87
May 17, 2022 Corporate PDF241 KB

Nippon Shinyaku Provides Assistance to Ukraine
May 11, 2022 Management & Finance

Outline of Consolidated Financial Results for the Year Ended March 31, 2022
March 28, 2022 Pharmaceuticals PDF285 KB

Marketing approval of MonoVer for I.V. injection 500mg/1000mg by MHLW for the treatment of iron deficiency anemia
March 17, 2022 R & D PDF260 KB

The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
March 11, 2022 R & D PDF259 KB

The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
March 07, 2022 Pharmaceuticals PDF338 KB

Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Chronic Lymphocytic Leukemia
February 10, 2022 Management & Finance PDF547 KB

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2021
January 26, 2022 Corporate PDF270 KB

Nippon Shinyaku Establishes a Local Subsidiary in Tianjin, China
January 25, 2022 Pharmaceuticals PDF245 KB

Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in US

by Year

2025
2024
2023
2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009

by Category

Corporate
Management & Finance
Pharmaceuticals
R & D
Sustainability
Food Business
Other
Notices

Top
PressReleases / Notice2022